ACAD | Zacks Investment Research Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) to Sell

ACADIA Pharmaceuticals (NASDAQ:ACAD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Monday, Zacks.com reports.They currently have a $53.00 target price on the biopharmaceutical company’s stock.Zacks Investment Research‘s price objective indicates a potential upside of 3.29% from the company’s previous close.According to […]Transcript Daily

ACAD | Jefferies Financial Group Weighs in on ACADIA Pharmaceuticals Inc.’s FY2022 Earnings (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) – Jefferies Financial Group dropped their FY2022 earnings estimates for ACADIA Pharmaceuticals in a report released on Thursday, November 5th.Jefferies Financial Group analyst C.Howerton now expects that the biopharmaceutical company will earn $0.91 per share for the year, down from their previous estimate of $1.01.Jefferies Financial Group currently […]Daily Political

ACAD | ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $58.00 Price Target at Morgan Stanley

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target upped by equities researchers at Morgan Stanley from $57.00 to $58.00 in a note issued to investors on Thursday, AR Network reports.The firm presently has an “overweight” rating on the biopharmaceutical company’s stock.Morgan Stanley’s target price would suggest a potential upside of 15.56% from the stock’s […]Daily Political

ACAD | Srdjan R. Stankovic Sells 1,297 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) President Srdjan R.Stankovic sold 1,297 shares of ACADIA Pharmaceuticals stock in a transaction on Friday, October 16th.The stock was sold at an average price of $42.56, for a total value of $55,200.32.Following the transaction, the president now directly owns 14,303 shares of the company’s stock, valued at approximately […]The Lincolnian